Clinical Trials Logo

Clinical Trial Summary

This is a prospective randomised clinical trial study to test an artificial intelligence (AI)-assisted continuous electroencephalogram(cEEG) diagnostic tool for optimizing the administration of antiseizure medication (ASM) in neonatal intensive care units(NICUs).

Clinical Trial Description

The occurrence of neonatal seizures may be the first, and perhaps the only, clinical sign of a central nervous system disorder in the newborn infant. The promoted treatment of seizures can limit the secondary injury to the brain and positively affect the infant's long-term neurological development. However, the current antiseizure medication (ASM) are both overused and underused. Studies indicated that early automated seizure detection tool had a high diagnostic accuracy of neonatal seizures. However, there is little evidence that early automated seizure detection tool could the optimize the administration of ASM and improved the neurological outcomes in neonatal seizures. Therefore, the primary study aim is to investigate whether the utility of AI assisted cEEG diagnostic tool could optimize the administration of ASM in NICUs. This project will enroll the neonates with suspected or high risk of seizures who will receive at least 72 hours cEEG monitoring during hospitalization. All the cEEG monitoring methodology is standardized across recruiting hospitals. The intervention will be an artificial intelligence (AI)-assisted continues electroencephalogram (cEEG) diagnostic tool. The individuals were randomly allocated to one of the two groups using a predetermined randomisation sequence and block randomisation generator (block of 4). The group 1 will be monitored with cEEG and the cEEG recording will be assessed by neonatologists with AI assisted cEEG diagnostic tool in real time during cEEG monitoring. The group 2 will be monitored with cEEG and the cEEG recording will be assessed by neonatologists when as routine during cEEG monitoring. Both groups will follow the standard clinical protocols for ASM administration of the recruiting hospitals The reference standard is the electrographic seizures interpreted by 3 clinicians who had attended the uniformly training program and were certified by the Chinese Anti-Epilepsy Association. These 3 clinicians are blinded to the group allocation. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05036395
Study type Interventional
Source Children's Hospital of Fudan University
Contact Wenhao Zhou, Ph.D
Phone +86-21-64931913
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date September 20, 2021
Completion date September 20, 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04991779 - AI-assisted cEEG Diagnosis of Neonatal Seizures in Neonatal Intensive Care Unit
Withdrawn NCT03602118 - Study to Evaluate Phenobarbital Sodium Injection for the Treatment of Neonatal Seizures Phase 3
Not yet recruiting NCT04831242 - Monitoring Key Activity and Physiology of Neonates in Intensive Care
Completed NCT01224457 - Effect of CYP2C9/CYP2C19 Polymorphism on Pharmacokinetics of Phenobarbital in Korean Neonatal Seizure Patients. N/A
Recruiting NCT04337697 - Neonatal Seizure Registry - Developmental Functional EValuation
Withdrawn NCT03996317 - Maternal Hyperoxygenation for Intrapartum Fetal Heart Rate Tracing Abnormalities N/A
Not yet recruiting NCT03786497 - Protecting Brains and Saving Futures - the PBSF Protocol
Completed NCT01747863 - Prospective Research in Infants With Mild Encephalopathy N/A
Recruiting NCT04259125 - Evaluating the Role of Inflammation in Neonatal Epileptogenesis